(Reuters) - German biotech CureVac B.V., which is in early stages of testing its coronavirus vaccine, said on Monday it expects to raise up to $213 million in its U.S. initial public offering (IPO).
CureVac said it expects its offering of 13.33 million shares to be priced between $14.00 and $16.00 per share.
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Saumyadeb Chakrabarty)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)